Glenmark Pharmaceuticals recalled 26,928 packs of Viorele oral contraceptives on September 3, 2025. The recall follows the discovery of impurity issues in the product. Consumers should stop using the affected tablets immediately and contact healthcare providers for guidance.
Failed Impurities/Degradation Specifications
Consumers and healthcare providers should stop using this product immediately. Contact Glenmark Pharmaceuticals Inc., USA or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Viorele, containing Desogestrel and Ethinyl Estradiol, with dosages of 0.15 mg/0.02 mg and 0.01 mg. Each pack consists of three blisters, each containing 28 tablets. The product was distributed across the United States.
The recall was initiated due to failed impurities and degradation specifications. These issues can potentially compromise the safety and efficacy of the medication, posing a risk to consumers.
There are no reported incidents or injuries associated with the use of the recalled product. Consumers are advised to take immediate action, as the failure of specifications can lead to health risks.
Consumers should stop using Viorele tablets immediately. Contact Glenmark Pharmaceuticals Inc. or your healthcare provider for further guidance and potential return options.
For more information, contact Glenmark Pharmaceuticals at their official website or by phone. Additional details can be found at the FDA recall page.
Get instant alerts for recalls that affect you. Free forever.
Glenmark Pharmaceuticals recalled nearly 97,000 packs of Ondansetron Orally Disintegrating Tablets on December 30, 2025. Defective blister packs may not fully seal, leading to tablets falling out. Consumers should stop using the product immediately and contact healthcare providers.
Novo Nordisk recalled Wegovy (semaglutide) injections on December 19, 2025, after discovering hair in prefilled syringes. The contamination poses a serious hazard to consumers. The recall affects all units distributed nationwide.
Novo Nordisk recalled Wegovy (semaglutide) Injection on December 19, 2025, due to hair found in a prefilled syringe. The recall affects products distributed nationwide in the United States. Consumers should stop using the product immediately and contact their healthcare provider.
Zydus Pharmaceuticals recalled over 2,100 bottles of TraZODONE Hydrochloride Tablets on December 19, 2025. Some tablets have surface dents that may affect medication integrity. Consumers should stop using the product immediately and seek guidance from healthcare providers.
CareFusion 213, LLC recalled 106,400 units of ChloraPrep Triple Swabsticks on December 17, 2025. The recall occurred due to a lack of assurance of sterility. Consumers must stop using the product immediately and contact CareFusion for guidance.
Merck Sharp & Dohme LLC recalled 845 kits of Noxafil Powdermix on December 12, 2025. The recall follows the discovery of potential metal particulates in the product. Consumers should stop using the medication immediately and contact their healthcare provider for further guidance.
Merck Sharp & Dohme LLC recalled 3 single-dose kits of Emend (aprepitant) on December 12, 2025. The recall stems from the potential presence of metal particulates in the medication. Consumers should immediately stop using the product and contact their healthcare provider for guidance.
Beaver-Visitec International recalled five units of the OME6000U Laser and Endoscopy System on December 5, 2025. The recall stems from a manufacturing deviation where ferrites required for the USB cable were not installed. This omission poses a high electrical hazard risk to patients and healthcare providers.